Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.

Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, Makoto Tahara, Lisa Licitra, Danny Rischin, John Waldron, Christian Simon, Vincent Gregoire, Kevin Harrington, Gustavo Vasconcelos Alves, Iane Pinto Figueiredo Lima, Yoann Pointreau, Brett G. M Hughes, Sercan Aksoy, Marcin Hetnal, Joy Y. Ge, Holly Brown, Jonathan Cheng, Behzad BidadiLillian L. Siu

Research output: Contribution to journalArticlepeer-review

Abstract

Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC. Clinical Trial Registration: NCT03040999 (ClinicalTrials.gov).
Original languageEnglish
JournalFuture Oncology
Issue number18
Publication statusPublished - Jun 1 2020

Fingerprint Dive into the research topics of 'Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.'. Together they form a unique fingerprint.

Cite this